彭布罗利珠单抗
医学
内科学
危险系数
头颈部鳞状细胞癌
肿瘤科
化疗
四分位间距
头颈部癌
西妥昔单抗
人口
放射治疗
癌症
免疫疗法
置信区间
结直肠癌
环境卫生
作者
Kevin J. Harrington,Barbara Burtness,Richard Greil,Denis Soulières,Makoto Tahara,Gilberto de Castro,Amanda Psyrri,Irene Braña,Neus Basté,Prakash Neupane,Åse Bratland,Thorsten Fuereder,Brett Hughes,Ricard Mesı́a,Nuttapong Ngamphaiboon,Tamara Rordorf,Wan Zamaniah Wan Ishak,Jianxin Lin,Burak Gümüşçü,Ramona F. Swaby,Danny Rischin
摘要
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented.
科研通智能强力驱动
Strongly Powered by AbleSci AI